Abstract
The value of a radioimmunoassay (RIA) in the detection of the human carcinoma-associated antigen CA-50 has been assessed in 50 normal subjects, 28 patients with various benign liver diseases and 91 patients with primary and secondary liver carcinomas. Sera from all normal subjects and 25 of 28 (89 per cent) patients with benign liver diseases had a CA-50 level below 17 units/ml. Three patients with sclerosing cholangitis and sixty (66 per cent) patients with primary or secondary liver tumours had CA-50 levels above 17 units/ml. CA-50 may therefore be a useful tumour marker for the diagnosis of liver carcinomas and for the post-treatment monitoring of patients with various liver malignancies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
